AMARIN CORP PLC\UK Derivative Liability
AMARIN CORP PLC\UK (AMRN) had Derivative Liability of $3.61 million as of 2016-06-30, per its 10-Q filed 2016-08-04.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2017-03-01
- 2016-06-30: Derivative Liability $3.61M.
- 2016-03-31: Derivative Liability $9.42M.
- 2015-12-31: Derivative Liability $8.17M.
- 2015-09-30: Derivative Liability $6.93M.
| Period end | Derivative Liability |
|---|---|
| 2016-06-30 | $3.61M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $9.42M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $8.17M 10-K · filed 2017-03-01 |
| 2015-09-30 | $6.93M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $6.70M 10-Q · filed 2016-08-04 |
| 2015-03-31 | $6.10M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $7.52M 10-K · filed 2017-03-01 |
| 2014-09-30 | $9.12M 10-Q · filed 2015-11-04 |
| 2014-06-30 | $13.91M 10-Q · filed 2015-08-06 |
| 2014-03-31 | $13.53M 10-Q · filed 2015-05-08 |
| 2013-12-31 | $17.99M 10-K · filed 2016-02-25 |
| 2013-09-30 | $47.19M 10-Q · filed 2014-11-06 |
| 2013-06-30 | $45.52M 10-Q · filed 2014-08-07 |
| 2013-03-31 | $65.36M 10-Q · filed 2014-05-09 |
| 2012-12-31 | $69.43M 10-K · filed 2015-03-03 |
| 2012-09-30 | $90.96M 10-Q · filed 2013-11-07 |
| 2012-06-30 | $120.21M 10-Q · filed 2013-08-08 |
| 2011-12-31 | $123.13M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |